FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 1483 - National Cancer Institute Board of Scientific Advisors - Authorized by Law

GENERAL INFORMATION

Committee Name	National Cancer Institute Board of Scientific Advisors	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	1483
Original Establishment Date	11/20/1985	Committee Status	Terminated
Actual Termination Date	4/1/2025	Committee URL	http://N/A
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	35
Terminated This FY	Yes	Designated Fed Officer Position Title*	DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	10/8/2023	Designated Federal Officer First Name*	PAULETTE
Date Of Renewal Charter	10/8/2025	Designated Federal Officer Middle Name	S.
Projected Termination Date		Designated Federal Officer Last Name*	GRAY
Exempt From Renewal*	No	Designated Federal Officer Suffix	PH.D.
Specific Termination Authority	2025 Secretary Directive	Designated Federal Officer Phone*	240-276-6340
Establishment Authority*	Authorized by Law	Designated Federal Officer Fax*	240-276-7815
Specific Establishment Authority*	42 U.S.C. 285a-2(b)(7)	Designated Federal Officer Email*	grayp@mail.nih.gov
Effective Date Of Authority*	11/20/1985
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Board was composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provided scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. It included the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considered meritorious and consistent with the Institute’s programs. The advisory role of the Board was scientific and did not include deliberation on matters of public policy. In FY2025, the BSA presented reports on various topics related to cancer research in general as well as legislative matters. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: The Experimental Therapeutics Clinical Trials Network (ETCTN) (Re-issue RFA/Coop. Agr.), NCI Community Oncology Research Program (NCORP) (Re-issue RFA), Phase 4: U.S. and Low- and Middle-Income Countries (LMICs) HIV Associated Malignancy Research Centers (RFA/Coop. Agr.), Global Training for Research and Equity in Cancer (GlobTREC) (Re-issue RFA/Coop. Agr.), Cancer Intervention and Surveillance Modeling Network (CISNET) Reissue (U01 Clinical Trial Not Allowed (RFA/Coop. Agr.), Informatics Technology for Cancer Research (ITCR) (Re-issue RFA/Coop. Agr.).
How is membership balanced?*	The Board consisted of up to 35 members, including a Chair appointed by the NCI Director. Members are selected from authorities with expertise across a wide range of fields, including laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations were addressed in selecting members for appointment to the Board.
How frequent & relevant are cmte mtgs?*	Meetings were typically held three times per year. During this reporting period, the committee convened once following its termination, meeting jointly with the National Cancer Advisory Board at the virtual session in November 2024. The Board’s deliberations were essential to reviewing a significant portion of the Institute’s extramural program, including concept reviews of Requests for Applications (RFAs), Program Announcements with special receipt, referral, and review (PARs), and Research and Development (R&D) Requests for Proposals (RFPs) for contract initiatives.
Why advice can't be obtained elsewhere?*	This Board was composed of distinguished biomedical research authorities from outside the NIH, ensuring unbiased and objective evaluations of extramural research programs. Their recommendations were invaluable, as the complexity of the research required a unique breadth and balance of expertise not otherwise available within the NIH or from other established sources.
Why close or partially close meetings?	N/A
Recommendation Remarks	Per the 2025 Secretary Directive, this FACA Committee has been terminated and no longer maintains a website. Reports: The committee did not produce any public reports. Max Number of Members Total: The Charter authorized up to 35 members, including the Chair. At the time of termination, the committee had 30 SGE members. Members: Member term end dates differ from those reported in the FY2024 ACR due to the committee’s termination. Eight members were on-boarded in FY2025 [Suzanne D. Conzen, Debra L. Friedman, William C. Hahn, Wells A. Messersmith, Katherine A. Rendle, Charles M. Rudin, George J. Weiner, and Kris C. Wood]. DFO/Committee Decision Maker: These roles are held by the same individual based on the Institute’s assignment of responsibilities.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	No	Action Reallocate Resources	Yes
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	No
Outcome Increased Customer Satisfaction	No	Action Comment	Priorities were reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources were allocated based on approved concepts.
Outcome Implement Laws/Reg Requirements	No	Grants Review*	No
Outcome Other	Yes	Number Of Grants Reviewed	0
Outcome Comment	Based on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, behavioral modifications and cures for different cancer sites. Another outcome was the annual posting of the RFA Report.	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	Meetings were held not less than three times a year. The committee met one time during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual November 2024. The Board also met virtually in March 2024. The Board’s deliberations were essential to reviewing a significant portion of the Institute’s extramural program, including concept reviews of Requests for Applications (RFAs), Program Announcements with special receipt, referral, and review (PARs), and Research and Development (R&D) Requests for Proposals (RFPs) for contract initiatives.	Grants Review Comment	NA
Number Of Recommendations*	557	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	In addition to general recommendations, specific recommendations by the committee include: 1. A motion to concur on the DCTD’s re-issue RFA/Coop. Agr. entitled “The Experimental Therapeutics Clinical Trials Network (ETCTN)” was approved unanimously. 2. A motion to concur on the DCP’s re-issue RFA entitled “NCI Community Oncology Research Program (NCORP)” was approved unanimously. 3. A motion to approve the DCTD’s new PAR entitled “Cancer Tissue-on-Chip (ToC) Technologies for Improved Preclinical Efficacy Evaluation of Therapies in Oncology” was approved with 21 ayes, 0 nays, 0 abstentions, and 7 deferrals. 4. A motion to approve the Office of the Director’s (OD) new RFA/Coop. Agr. entitled “Phase 4: U.S. and Low- and Middle-Income Countries (LMICs) HIV-Associated Malignancy Research Centers” was approved unanimously. 5. A motion to concur on DCCPS’ re-issue RFA/Coop. Agr. entitled “Cancer Intervention and Surveillance Modeling Network (CISNET) Re-issuance (U01 Clinical Trial Not Allowed)” was approved unanimously. 6. A motion to approve the OD’s new PAR entitled “The Academic Career Excellence (ACE) Award, Including Awards to Promote Diversity” was approved unanimously. 7. A motion to concur on the OD’s re-issue RFA/Coop. Agr. entitled “Informatics Technology for Cancer Research (ITCR)” was approved unanimously. 8. A motion to approve the OD’s new PAR entitled “Cancer Moonshot Scholars Program” was approved unanimously.	Access Agency Website	Yes
% of Recs Fully Implemented*	90.00%	Access Committee Website	No
% of Recs Fully Implemented Comment	The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	10.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	The percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.	Access Other	Yes
Agency Feedback*	Yes	Access Comment	Information on the BSA was available on the NCI Division of Extramural Activities website (http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm),which included each committee’s charter, minutes, agenda, roster, future meeting dates, presentations, and reports. BSA meetings were also accessible to the public, live and on demand, via the NIH Videocast (http://videocast.nih.gov/).
Agency Feedback Comment*	The NCI Director’s Report was presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report was presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items was assigned to individual NCI staff with specific time frames with deadlines. Information was provided to the public at each meeting.	Narrative Description*	NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor’s (BSA). The BSA was composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provided scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This included the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA was scientific and did not include deliberation on matters of public policy. The BSA represented the scientific community's voice in the extramural science the NCI supports. As such, the Board advised the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluated NCI extramural programs, and reviewed ideas for new research opportunities and solicitations to ensure that a concept was meritorious and consistent with the Institute's mission. Additionally, the BSA believed it was important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA’s deliberations were an indispensable part of the review of a very large part of the Institute's extramural program.

COSTS

1. Payments to Non-Federal Members*	$7,800.00	1. Est Paymnts to Non-Fed Membrs Nxt FY*	$0.00
2. Payments to Federal Members*	$0.00	2. Est. Payments to Fed Members Next FY*	$0.00
3. Payments to Federal Staff*	$85,710.00	3. Estimated Payments to Federal Staff*	$0.00
4. Payments to Consultants*	$0.00	4. Est. Payments to Consultants Next FY*	$0.00
5. Travel Reimb. For Non-Federal Membrs*	$0.00	5. Est Travel Reimb Non-Fed Membr nxtFY*	$0.00
6. Travel Reimb. For Federal Members*	$0.00	6. Est Travel Reimb For Fed Members*	$0.00
7. Travel Reimb. For Federal Staff*	$0.00	7. Est. Travel Reimb to Fed Staf Nxt FY*	$0.00
8. Travel Reimb. For Consultants*	$0.00	8. Est Travel Reimb to Consltnts Nxt FY*	$0.00
10. Other Costs	$13,820.00	10. Est. Other Costs Next FY*	$0.00
11. Total Costs	$107,330.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	9/12/2025 2:47 PM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*	0.40	Est Cost Remarks	Committee has been terminated.
Cost Remarks	Actual costs are lower than those projected in FY2024 due to the termination of the committee.

Interest Areas

Category Area Health Treatment Medicine Diseases Health and Health Research

Custom Links

Committee Level Reports